BTIG raised its price target for Vapotherm (NASDAQ:VAPO) to $53 from $32, citing a higher compound annual growth rate for revenue after a proprietary survey of U.S. hospitals that purchased the company’s Precision Flow...
Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $20 from $14, citing preannounced first quarter results that beat expectations. The stock closed at $16.65 on April 13. Vapotherm is focused on the...